Twist Bioscience Registers Invenra Share Resale Prospectus
I'm LongbridgeAI, I can summarize articles.Twist Bioscience (TWST) filed a prospectus supplement to register the resale of shares issued to Invenra Inc. under a February 11, 2026 Stock Purchase Agreement, accompanied by a legal opinion from Orrick, Herrington & Sutcliffe LLP. While recent analyst ratings assign a 'Buy' with an $115 target, TipRanks’ AI Analyst Spark rates TWST as Neutral due to weak financial performance and cash burn, despite positive technicals and supportive corporate events.
An update from Twist Bioscience ( (TWST) ) is now available.
Twist Bioscience Corporation has filed a prospectus supplement to register the resale of shares issued to Invenra Inc. under a Stock Purchase Agreement dated February 11, 2026. In connection with this registration, the company submitted a legal opinion from Orrick, Herrington & Sutcliffe LLP, formalizing the process for Invenra’s potential resale of its Twist Bioscience shares.
The most recent analyst rating on (TWST) stock is a Buy
with a $115.00 price target.
To see the full list of analyst forecasts on Twist Bioscience stock,
see the TWST Stock Forecast page.
Spark’s Take on TWST Stock
According to Spark, TipRanks’ AI Analyst, TWST is a Neutral.
The score is held back primarily by weak financial performance driven by persistent losses and significant cash burn, despite improving revenue and gross margins and a relatively solid balance sheet. Technicals are a major offset with strong upward trend and favorable momentum, while valuation remains challenged due to negative earnings. The latest earnings call and recent corporate events are supportive (raised guidance, path to EBITDA breakeven, and strengthened liquidity via an equity raise), but execution toward sustainable cash flow remains the key swing factor.
To see Spark’s full report on TWST stock,
click here.
More about Twist Bioscience
Twist Bioscience Corporation operates in the biotechnology sector, focusing on synthetic DNA manufacturing and related genomic technologies. The company serves pharmaceutical, biotech, and research customers by providing high-precision DNA products and services that support drug discovery, diagnostics, and other life sciences applications.
Average Trading Volume: 1,776,010
Technical Sentiment Signal: Buy
Current Market Cap: $8.19B
For an in-depth examination of TWST stock, go to TipRanks’ Overview page.